September 23, 2022 01:48 PM EDT
Pharma
FDA+
Manufacturing

An­oth­er Cipla site lands a Form 483 over clean­ing is­sues and QC con­trols

Tyler Patchen

News Reporter

A Cipla drug man­u­fac­tur­ing site in In­dia has once again land­ed in the crosshairs of FDA in­spec­tors.

The fa­cil­i­ty in ques­tion is Cipla’s drug man­u­fac­tur­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

An­thos' de­tailed mid-stage da­ta back its an­ti­co­ag­u­lant, but can the drug suc­ceed where Bay­er's failed?

Te­va’s MS drug and gener­ics to add black box warn­ing for ana­phy­lax­is

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

Chi­nese start­up be­gins first tri­al of in vi­vo CRISPR ther­a­py for blood dis­ease

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times